Skip to main content
. 2020 Apr 20;12(1):1746520. doi: 10.1080/19420862.2020.1746520

Figure 6.

Figure 6.

Saturation of IL-36 R target in vivo normalizes M616 serum pharmacokinetics in C57BL/6 mouse. M616 was administered IV at 0.5 mg/kg alone, or in combination with 10 mg/kg competitive mAb chM616 dosed as a cassette. A species-selective immunoassay was used to monitor the pharmacokinetics of M616 in the presence of chM616.